Coronavirus 2019 (COVID-19) is an unexpected pandemic that has caused a state of emergency, as well as generating drastic changes in clinical care protocols. Some drugs commonly used in rheumatoid arthritis, systemic lupus erythematosus, and other systemic autoimmune diseases have been described for its treatment. Therefore, there is an imminent risk of shortages. The aim of this narrative review and expert opinion is to present general recommendations on the clinical and administrative management of outpatients with autoimmune or systemic inflammatory disease, in the context of the COVID-19 pandemic.
|Translated title of the contribution||Recommendations for rheumatologists on pharmacological management during the COVID-19 health emergency: Expert group opinion|
|Number of pages||7|
|Journal||Revista Colombiana de Reumatologia|
|State||Published - 1 Apr 2021|
Bibliographical notePublisher Copyright:
© 2020 Asociación Colombiana de Reumatología